The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|July 16, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
- Volume 11
- Issue 8
EAG Acquires ABC Laboratories
Author(s)Pharmaceutical Technology Editors
Evans Analytical Group expands into the pharmaceutical/biopharmaceutical industry with acquisition of ABC Laboratories.
Advertisement
Evans Analytical Group (EAG), an independent laboratory network providing analytical and testing to the agrochemical and pharmaceutical industries, announced on July 8 that it has acquired Analytical Bio-Chemistry Laboratories (ABC Laboratories) of Columbia, MO. Financial terms of the transaction were not disclosed.
ABC Laboratories offers development and CGMP and GLP-compliant testing capabilities for small- and large-molecule therapies and medical devices through its
EAG is private company, majority owned by
Sources:
Articles in this issue
about 11 years ago
CDMOs Move Slowly with Expansion Plansabout 11 years ago
Accelerating Continuous API Synthesisabout 11 years ago
BioOutsource Opens New Facility in Glasgowabout 11 years ago
Silicone Rubber Pieces Spur Recall of Teva Productabout 11 years ago
Baxter Recalls IV Solution for Container and Particulate Issuesabout 11 years ago
Indian API Manufacturer Cited for Recordkeeping Failuresabout 11 years ago
Xcelience Makes Investment in Powdersizeabout 11 years ago
FDA Issues Quality Metrics Draft Guidance Document for Commentabout 11 years ago
EMA Issues Guideline on Fast Tracking Drugs for Unmet NeedsAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Advertisement
Advertisement